image
Healthcare - Medical - Devices - NASDAQ - US
$ 3.28
-3.81 %
$ 57.5 M
Market Cap
-2.54
P/E
1. INTRINSIC VALUE

enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.[ Read More ]

The intrinsic value of one NVNO stock under the base case scenario is HIDDEN Compared to the current market price of 3.28 USD, enVVeno Medical Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart NVNO

image
FINANCIALS
0 REVENUE
0.00%
-25.2 M OPERATING INCOME
-1.23%
-23.5 M NET INCOME
4.67%
-18.9 M OPERATING CASH FLOW
-20.74%
-7.87 M INVESTING CASH FLOW
77.23%
25.8 M FINANCING CASH FLOW
0.00%
0 REVENUE
0.00%
-6.17 M OPERATING INCOME
-13.13%
-5.64 M NET INCOME
-13.84%
-4.28 M OPERATING CASH FLOW
-9.42%
6.22 M INVESTING CASH FLOW
56.52%
-24.7 M FINANCING CASH FLOW
0.00%
Balance Sheet Decomposition enVVeno Medical Corporation
image
Current Assets 46.9 M
Cash & Short-Term Investments 46.4 M
Receivables 0
Other Current Assets 511 K
Non-Current Assets 1.71 M
Long-Term Investments 0
PP&E 1.68 M
Other Non-Current Assets 31 K
Current Liabilities 1.37 M
Accounts Payable 427 K
Short-Term Debt 676 K
Other Current Liabilities 268 K
Non-Current Liabilities 1.06 M
Long-Term Debt 1.06 M
Other Non-Current Liabilities 0
EFFICIENCY
Earnings Waterfall enVVeno Medical Corporation
image
Revenue 0
Cost Of Revenue 546 K
Gross Profit -546 K
Operating Expenses 25.2 M
Operating Income -25.2 M
Other Expenses -1.72 M
Net Income -23.5 M
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-50.90% ROE
-50.90%
-48.35% ROA
-48.35%
-54.23% ROIC
-54.23%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis enVVeno Medical Corporation
image
Net Income -23.5 M
Depreciation & Amortization 546 K
Capital Expenditures -33 K
Stock-Based Compensation 5.2 M
Change in Working Capital -616 K
Others -863 K
Free Cash Flow -18.9 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets enVVeno Medical Corporation
image
NVNO has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership enVVeno Medical Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
51.8 K USD 1
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
8 months ago
Mar 13, 2024
Sell 51.8 K USD
Alavi Hamed
Chief Technology Officer
- 8334
6.22 USD
2 years ago
Aug 16, 2022
Bought 47.6 K USD
Duhay Francis
director:
+ 7751
6.14 USD
2 years ago
Jun 30, 2022
Bought 3.85 K USD
Shrivastava Sanjay
director:
+ 1000
3.85 USD
2 years ago
Jun 27, 2022
Bought 9.5 K USD
BERMAN ROBERT ANDREW
Chief Executive Officer
+ 2500
3.8 USD
2 years ago
Nov 19, 2021
Bought 14.9 K USD
BERMAN ROBERT ANDREW
CEO
+ 2000
7.43 USD
2 years ago
Nov 19, 2021
Bought 14.9 K USD
BERMAN ROBERT ANDREW
CEO
+ 2000
7.43 USD
3 years ago
Nov 16, 2021
Bought 15.7 K USD
BERMAN ROBERT ANDREW
CEO
+ 2000
7.87 USD
3 years ago
Nov 16, 2021
Bought 15.7 K USD
BERMAN ROBERT ANDREW
CEO
+ 2000
7.87 USD
3 years ago
Aug 25, 2021
Bought 10 K USD
Jenusaitis Matthew
Director
+ 1300
7.7 USD
3 years ago
Jun 16, 2021
Bought 12.5 K USD
Gray Robert
Director
+ 2000
6.25 USD
3 years ago
May 21, 2021
Bought 9.44 K USD
Glickman Marc H.
SVP & Chief Medical Officer
+ 1600
5.9 USD
3 years ago
May 18, 2021
Bought 16.4 K USD
BERMAN ROBERT ANDREW
Chief Executive Officer
+ 3000
5.47 USD
3 years ago
May 18, 2021
Bought 16.4 K USD
BERMAN ROBERT ANDREW
Chief Executive Officer
+ 3000
5.47 USD
3 years ago
May 17, 2021
Bought 50.6 K USD
Duhay Francis
Director
+ 9492
5.33 USD
4 years ago
Jun 11, 2020
Sell 39 K USD
Biodyne Holding, S.A.
- 100000
0.39 USD
4 years ago
Jun 15, 2020
Sell 42 K USD
Biodyne Holding, S.A.
- 100000
0.42 USD
4 years ago
Jun 16, 2020
Sell 64.5 K USD
Biodyne Holding, S.A.
- 150000
0.43 USD
4 years ago
Jun 17, 2020
Sell 97.5 K USD
Biodyne Holding, S.A.
- 203100
0.48 USD
4 years ago
Jun 18, 2020
Sell 27.7 K USD
Biodyne Holding, S.A.
- 61640
0.45 USD
4 years ago
Jun 19, 2020
Sell 36.8 K USD
Biodyne Holding, S.A.
- 80000
0.46 USD
4 years ago
Jun 22, 2020
Sell 29.1 K USD
Biodyne Holding, S.A.
- 63186
0.46 USD
4 years ago
Jun 23, 2020
Sell 34.4 K USD
Biodyne Holding, S.A.
- 80000
0.43 USD
4 years ago
Jun 24, 2020
Sell 23.3 K USD
Biodyne Holding, S.A.
- 55530
0.42 USD
4 years ago
Jun 25, 2020
Sell 40 K USD
Biodyne Holding, S.A.
- 100000
0.4 USD
4 years ago
Jun 26, 2020
Sell 30.4 K USD
Biodyne Holding, S.A.
- 80000
0.38 USD
4 years ago
Jun 29, 2020
Sell 26.6 K USD
Biodyne Holding, S.A.
- 68094
0.39 USD
4 years ago
Jul 01, 2020
Sell 17.1 K USD
Biodyne Holding, S.A.
- 45000
0.38 USD
4 years ago
Jul 02, 2020
Sell 22.8 K USD
Biodyne Holding, S.A.
- 57000
0.4 USD
4 years ago
Jul 06, 2020
Sell 2.52 K USD
Biodyne Holding, S.A.
- 6450
0.39 USD
4 years ago
Jul 16, 2020
Sell 19 K USD
Biodyne Holding, S.A.
- 50000
0.38 USD
4 years ago
Jul 17, 2020
Sell 19 K USD
Biodyne Holding, S.A.
- 50000
0.38 USD
4 years ago
Jul 20, 2020
Sell 64.5 K USD
Biodyne Holding, S.A.
- 150000
0.43 USD
4 years ago
Jul 21, 2020
Sell 22.5 K USD
Biodyne Holding, S.A.
- 50000
0.45 USD
4 years ago
Jul 30, 2020
Sell 8 K USD
Biodyne Holding, S.A.
- 25000
0.32 USD
4 years ago
Jul 31, 2020
Sell 1.7 K USD
Biodyne Holding, S.A.
- 5000
0.34 USD
4 years ago
Aug 03, 2020
Sell 22.4 K USD
Biodyne Holding, S.A.
- 70000
0.32 USD
4 years ago
Aug 14, 2020
Sell 15.5 K USD
Biodyne Holding, S.A.
- 50000
0.31 USD
4 years ago
Aug 18, 2020
Sell 17 K USD
Biodyne Holding, S.A.
- 50000
0.34 USD
4 years ago
Aug 19, 2020
Sell 15 K USD
Biodyne Holding, S.A.
- 50000
0.3 USD
4 years ago
Aug 20, 2020
Sell 20.2 K USD
Biodyne Holding, S.A.
- 75000
0.27 USD
4 years ago
Aug 21, 2020
Sell 28.5 K USD
Biodyne Holding, S.A.
- 75000
0.38 USD
4 years ago
Jun 02, 2020
Sell 72.6 K USD
Biodyne Holding, S.A.
10 percent owner
- 220000
0.33 USD
4 years ago
Jun 03, 2020
Sell 1.21 K USD
Biodyne Holding, S.A.
10 percent owner
- 3900
0.31 USD
4 years ago
Jun 03, 2020
Sell 522 USD
Biodyne Holding, S.A.
10 percent owner
- 1683
0.31 USD
5 years ago
Jun 07, 2019
Sell 459 K USD
Biodyne Holding, S.A.
Director
- 684813
0.67 USD
5 years ago
Mar 12, 2019
Bought 25 K USD
BERMAN ROBERT ANDREW
Chief Executive Officer
+ 18382
1.36 USD
5 years ago
Mar 12, 2019
Bought 25 K USD
BERMAN ROBERT ANDREW
Chief Executive Officer
+ 18382
1.36 USD
5 years ago
Mar 12, 2019
Bought 25 K USD
BERMAN ROBERT ANDREW
Chief Executive Officer
+ 21740
1.15 USD
5 years ago
Mar 12, 2019
Bought 25 K USD
BERMAN ROBERT ANDREW
Chief Executive Officer
+ 21740
1.15 USD
7. News
8. Profile Summary

enVVeno Medical Corporation NVNO

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 57.5 M
Dividend Yield 0.00%
Description enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
Contact 70 Doppler, Irvine, CA, 92618 https://www.envveno.com
IPO Date May 31, 2018
Employees 31
Officers Dr. Hamed Alavi Ph.D. Senior Vice President & Chief Technology Officer Dr. Marc H. Glickman M.D. Senior Vice President & Chief Medical Officer Dr. Benedict Broennimann M.D. Chief Medical Officer of Outside of United States Mr. Warren Hancock Co-founder Mr. Andrew Cormack Chief Commercial Officer Ms. Sandy Prietto Vice President of Marketing Mr. Robert A. Berman Chief Executive Officer & Director Mr. Craig Thomas Glynn Chief Financial Officer, Treasurer & Secretary